JP2023527612A - カンナビノイド組成物 - Google Patents

カンナビノイド組成物 Download PDF

Info

Publication number
JP2023527612A
JP2023527612A JP2022551351A JP2022551351A JP2023527612A JP 2023527612 A JP2023527612 A JP 2023527612A JP 2022551351 A JP2022551351 A JP 2022551351A JP 2022551351 A JP2022551351 A JP 2022551351A JP 2023527612 A JP2023527612 A JP 2023527612A
Authority
JP
Japan
Prior art keywords
cbga
pharmaceutical composition
cannabinoid
acid
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022551351A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023527612A5 (https=
Inventor
ペナー，ラインホールド
ピー． ネウパネ，ラム
小由里 鈴木
ファウジ，マリカ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Queens Medical Center
Original Assignee
Queens Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Queens Medical Center filed Critical Queens Medical Center
Publication of JP2023527612A publication Critical patent/JP2023527612A/ja
Publication of JP2023527612A5 publication Critical patent/JP2023527612A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01H—NEW PLANTS OR NON-TRANSGENIC PROCESSES FOR OBTAINING THEM; PLANT REPRODUCTION BY TISSUE CULTURE TECHNIQUES
    • A01H6/00—Angiosperms, i.e. flowering plants, characterised by their botanic taxonomy
    • A01H6/28—Cannabaceae, e.g. cannabis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D11/00—Solvent extraction
    • B01D11/02—Solvent extraction of solids
    • B01D11/0203—Solvent extraction of solids with a supercritical fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
JP2022551351A 2020-02-25 2021-02-24 カンナビノイド組成物 Pending JP2023527612A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062981424P 2020-02-25 2020-02-25
US62/981,424 2020-02-25
US202063072806P 2020-08-31 2020-08-31
US63/072,806 2020-08-31
PCT/US2021/019474 WO2021173718A1 (en) 2020-02-25 2021-02-24 Cannabinoid compositions

Publications (2)

Publication Number Publication Date
JP2023527612A true JP2023527612A (ja) 2023-06-30
JP2023527612A5 JP2023527612A5 (https=) 2024-03-04

Family

ID=77490171

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022551351A Pending JP2023527612A (ja) 2020-02-25 2021-02-24 カンナビノイド組成物

Country Status (6)

Country Link
US (1) US20230091336A1 (https=)
EP (1) EP4110045A4 (https=)
JP (1) JP2023527612A (https=)
AU (1) AU2021227227A1 (https=)
CA (1) CA3172868A1 (https=)
WO (1) WO2021173718A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202101732D0 (en) * 2021-02-08 2021-03-24 Tts Pharma Ltd A cannabinoid mixture
EP4415697A4 (en) * 2021-10-13 2025-08-20 Portland Tech Holdings Llc HEMP EXTRACT FOR THE TREATMENT OF PAIN, CANCER AND EPILEPSY IN ANIMALS
US12440454B2 (en) 2022-02-01 2025-10-14 Portland Technology Holdings Llc Pharmaceutical compositions containing hemp extract for administration to felines and related methods
WO2026038872A1 (ko) * 2024-08-13 2026-02-19 주식회사 네오켄바이오 신규한 화합물 및 이의 용도

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170143642A1 (en) * 2014-06-27 2017-05-25 Gw Pharma Limited Active pharmaceutical ingredient (api) comprising cannabinoids for use in the treatment of cancer
WO2018163164A1 (en) * 2017-03-05 2018-09-13 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) Compositions and methods for treating cancer
WO2018217803A2 (en) * 2017-05-22 2018-11-29 Growblox Life Sciences L.L.C. Myrcene-containing complex mixtures targeting trpv1
WO2019071302A1 (en) * 2017-10-09 2019-04-18 The University Of Sydney METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING EPILEPSY CRISES
WO2019199861A2 (en) * 2018-04-09 2019-10-17 Ellevet Sciences Hemp extract for treatment of pain in animals
WO2019226833A1 (en) * 2018-05-22 2019-11-28 Gbs Global Biopharma, Inc. Cannabinoids and/or terpenes for use in trpv1 modulation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1559423A1 (en) * 2004-02-02 2005-08-03 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Medicinal acidic cannabinoids
US10857107B2 (en) * 2017-02-01 2020-12-08 Gbs Global Biopharma, Inc. Cannabinoid-containing complex mixtures for the treatment of mast cell-associated or basophil-mediated inflammatory disorders
US10751380B2 (en) * 2018-03-08 2020-08-25 Alexander Kariman Compound and method for treating spasms, inflammation and pain
EP3813823A4 (en) * 2018-06-28 2022-08-10 Canopy Growth Corporation COMPOSITIONS AND METHODS FOR AGONIZING THE CB2 RECEPTOR

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170143642A1 (en) * 2014-06-27 2017-05-25 Gw Pharma Limited Active pharmaceutical ingredient (api) comprising cannabinoids for use in the treatment of cancer
WO2018163164A1 (en) * 2017-03-05 2018-09-13 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) Compositions and methods for treating cancer
WO2018217803A2 (en) * 2017-05-22 2018-11-29 Growblox Life Sciences L.L.C. Myrcene-containing complex mixtures targeting trpv1
WO2019071302A1 (en) * 2017-10-09 2019-04-18 The University Of Sydney METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING EPILEPSY CRISES
WO2019199861A2 (en) * 2018-04-09 2019-10-17 Ellevet Sciences Hemp extract for treatment of pain in animals
WO2019226833A1 (en) * 2018-05-22 2019-11-28 Gbs Global Biopharma, Inc. Cannabinoids and/or terpenes for use in trpv1 modulation

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ALEXANDER DIETRICH: ""Modulators of Transient Receptor Potential (TRP) Channels as Therapeutic Options in Lung Disease"", PHARMACEUTICALS, vol. 12, no. 1, JPN6025011926, 1 February 2019 (2019-02-01), pages 23, ISSN: 0005687850 *
L． DE PETROCELLIS ET AL.: ""Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to", ACTA PHYSIOLOGICA, vol. 204, no. 2, JPN6025011925, 12 August 2011 (2011-08-12), pages 255 - 266, ISSN: 0005687849 *
LEI ZHAN ET AL.: ""The role of TRPV4 in fibrosis"", GENE, vol. 642, JPN6025011927, February 2018 (2018-02-01), pages 1 - 8, ISSN: 0005687851 *
LUCIA RENEE RUHAAK ET AL.: ""Evaluation of the Cyclooxygenase Inhibiting Effects of Six Major Cannabinoids Isolated from Cannab", BIOLOGICAL AND PHARMACEUTICAL BULLETIN, vol. 34, no. 5, JPN6025011924, 2011, pages 774 - 778, ISSN: 0005687848 *
LUCIANO DE PETROCELLIS ET AL.: ""Effects of cannabinoids and cannabinoid‐enriched Cannabis extracts on TRP channels and endocannab", BRITISH JOURNAL OF PHARMACOLOGY, vol. 163, no. 7, JPN6025011923, 12 July 2011 (2011-07-12), pages 1479 - 1494, ISSN: 0005687847 *
SCOTT KA ET AL.: ""Enhancing the activity of cannabidiol and other cannabinoids in vitro through modifications to dru", ANTICANCER RESEARCH, vol. 33, no. 10, JPN6025011922, October 2013 (2013-10-01), pages 4373 - 80, ISSN: 0005687846 *

Also Published As

Publication number Publication date
AU2021227227A1 (en) 2022-10-13
WO2021173718A1 (en) 2021-09-02
US20230091336A1 (en) 2023-03-23
EP4110045A1 (en) 2023-01-04
EP4110045A4 (en) 2024-06-05
CA3172868A1 (en) 2021-09-02

Similar Documents

Publication Publication Date Title
JP2023527612A (ja) カンナビノイド組成物
US20230285303A1 (en) Rapidly infusing platform and compositions for therapeutic treatment in humans
JP2023527629A (ja) カンナビノイド組成物
JP2023549568A (ja) ヒトにおける治療的処置のための急速注入プラットフォーム及び組成物
AU2021390590B2 (en) Antiinflammatory compositions comprising cannabidiol, delta-9- tetrahydrocannabinol and linalool
EA038052B1 (ru) Комбинация, содержащая пальмитоилэтаноламид, для лечения хронической боли
AU2025220850A1 (en) Compositions for regulating homeostasis of cortisol and improving sleep quality and methods of use and production thereof
KR20060032598A (ko) 세로토닌 재흡수 억제제 및 아고멜라틴의 조합
JP2005533788A (ja) Ｐｄｅｉｖ阻害剤および抗うつ薬または不安解消薬の組み合わせによるうつ病および不安の治療
EP4014979B1 (en) Combination product comprising limonoids and sglt-2 inhibitors
KR0149491B1 (ko) 뇌혈관 장해치료제로서의 7-치환 아미노-8-치환카르보닐-메틸아미노-1-옥사스피로(4,5)데칸
KR101656834B1 (ko) 콜포신 다로페이트를 포함하는 골 질환의 예방 또는 치료용 조성물
JP2021073171A (ja) （ｒ）−ジミラセタム（１）と（ｓ）−ジミラセタム（２）を非ラセミ比で含む相乗的組成物
EA015483B1 (ru) ПРИМЕНЕНИЕ ИНГИБИТОРА p38 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ПСИХИАТРИЧЕСКИХ РАССТРОЙСТВ
WO2022246146A2 (en) Composition for treating autoimmune, alloimmune, inflammatory, and mitochondrial conditions, and uses thereof
MXPA06002504A (es) Combinacion de un inhibidor de recaptacion de serotonina y loxapina.
AU2021107263A4 (en) A composition and uses thereof
US20210128520A1 (en) Neuroprotective isoflavone compositions and methods
RU2858979C2 (ru) Антидепрессивное и анксиолитическое замещенное соединение циннамамид
Antidepressants 2.41 Bupropion
CN115403553A (zh) 一种抗抑郁和抗焦虑的取代桂皮酰胺化合物
CN103316019B (zh) 用于治疗抑郁症的包含选择性5-羟色胺再摄取抑制剂和糖皮质激素受体拮抗剂的药物组合
EP3328405A1 (en) Cis-and trans-suffruticosol d as therapeutic agents
JP2003104885A (ja) セロトニン再取り込み阻害剤の作用増強剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220830

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20230316

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230316

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230316

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240222

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250324

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250916